



S.I.Me.Ve.P.



S.I.Ve.M.P.

Settore IZS

CONVEGNO NAZIONALE

3^a GIORNATA DEI CENTRI E DEI LABORATORI
DI REFERENZA NAZIONALI
DEGLI ISTITUTI ZOOPROFILATTICI
SPERIMENTALI NELL'OTTICA ONE HEALTH

*"Esistono solo due cose: scienza ed opinione; la prima
genera conoscenza, la seconda ignoranza" (Ippocrate)*

Con il patrocinio:



S.I.Ve.M.P.
Sindacato Italiano Veterinari
di Medicina Pubblica

1 dicembre 2025

Ministero della Salute

AUDITORIUM "BIAGIO D'ALBA"
VIA G. RIBOTTA, 5 ROMA



Influenza nell'uomo

Antonio Piralla

*SS Laboratorio di Genomica e Bioinformatica
SC Microbiologia e Virologia
Fondazione IRCCS Policlinico San Matteo (Pavia)*

ONE IRCCS POLICLINICO SAN MATTEO






Influenza A : H1-H16 and N1-N9



Nachbagauer R et al. 2020 Nat Med

- ✓ Historically, influenza A human infections have been caused by three subtypes of hemagglutinin (H1, H2 and H3) and two neuraminidase subtypes (N1 and N2)
- ✓ In the last 20 years human infections by previously avian-only subtypes H5, H7 and H9 have been consistently reported.

Variability of influenza viruses



Next-generation influenza vaccines: opportunities and challenges

Chih-Jen Wei¹, Michelle C. Crank², John Shiver³, Barney S. Graham², John R. Mascola² and Gary J. Nabel¹ 

 Check for updates





Fig. 1: A spectrum of efficacy for influenza vaccines.

From: [Next-generation influenza vaccines: opportunities and challenges](#)



Vaccine	Coverage
Strain-specific	Circulating strains
Subtype-specific	Multiple strains within a single HA subtype
Multi-subtype	Multiple HA subtypes within group 1, group 2 or type B
Pan-group/lineage	Group 1 or 2 influenza A or influenza B lineages
Universal flu A	Influenza A
Universal flu A and B	Influenza A and B
'TRUE' universal	All strains. Single product. Multiple years.

Universality


How influenza viruses change??

Influenza viruses are constantly changing. They can change in two different ways:

- Antigenic «Drift»
- Antigenic «Shift»

While influenza viruses are changing by antigenic drift all the time, antigenic shift happens only occasionally.

Type A viruses undergo both kinds of changes; influenza type B viruses change only by the more gradual process of antigenic drift.




From zoonosis to pandemic

Chracteristics of pandemic virus


- ✓. Replication in humans
- ✓. Susceptibility of human population
- ✓. Human-human transmission

From pandemic to seasonal flu




Nachbagauer & Krammer, Clin Microbiol Inf, 2017

A



B



Series

Zoonoses 1

Ecology of zoonoses: natural and unnatural histories

William B Karesh, Andy Dobson, James O Lloyd-Smith, Juan Lubroth, Matthew A Dixon, Malcolm Bennett, Stephen Aldrich, Todd Harrington, Pierre Formenty, Elizabeth H Loh, Catherine C Machalaba, Mathew Jason Thomas, David L Heymann

Transmission of infection and amplification in people (bright red) occurs after a pathogen from wild animals (pink) moves into livestock to cause an outbreak (light green) that amplifies the capacity for pathogen transmission to people

Early detection and control efforts reduce disease incidence in people (light blue) and animals (dark green). Spillover arrows shows cross-species transmission.

Global Influenza Surveillance & Response System




Influenza pandemica

- Preparazione pandemica
- Monitoraggio e allerta

Influenza stagionale

- Sorveglianza epidemiologica
 - Stimare l'impatto della malattia
 - Definirne le caratteristiche epidemiologiche
- Sorveglianza virologica
 - Analizzare i virus stagionali circolanti
 - Formulare le raccomandazioni per la composizione vaccino

Potenziamento della sorveglianza virologica



Monitoraggio virologico di:

- *Persone ospedalizzate per sintomi respiratori* considerando anche il rischio di esposizione ad animali malati/morti
- *Casi di encefalite o meningoencefalite a eziologia non nota*
- *Cluster di infezioni respiratorie gravi*

In generale: qualsiasi campione positivo per virus influenzale A ma negativo per i sottotipi di virus influenzali stagionali deve essere caratterizzato prontamente

Preparazione pandemica e sorveglianza

A checklist for respiratory pathogen pandemic preparedness planning




World Health
Organization



CONTENTS

Acknowledgements	v
List of contributors	v
Abbreviations and acronyms	iv
I. Introduction	1
Preparing for respiratory pathogen pandemics	1
Purpose and scope	1
Audience and use	3
Structure of the checklist	3
II. System components and capacities for respiratory pathogen pandemic preparedness	4
1. Emergency coordination	4
1.1 Planning	4
2. Collaborative surveillance	
2.1 Surveillance: overarching system considerations	
2.2 Surveillance: early detection, investigation and assessment	
2.3 Surveillance: monitoring circulating pathogens and use of human health interventions	
2.4 Laboratory	
2.5 One Health/zoonotic disease: collaborative efforts	
3.4 Risk communication and community engagement	23
4. Clinical care	25
4.1 Health service provision: continuity of essential health services	25
4.2 Health service provision: case management	25
4.3 Infection prevention and control	27
4.4 Safe management of a dead body	29
• Box 2. Pathogen-specific priority actions for clinical care	29
5. Access to countermeasures	31
5.1 Health emergency response: emergency logistics and supply chain management	31
5.2 Equitable access, needs-based allocation and medical countermeasures deployment for pandemic products such as vaccines and antivirals – NDVP planning	32
• Box 3. Leveraging seasonal/routine influenza vaccination for pandemic response	33
5.3 Health emergency response: essential medicines, products and materials	35
5.4 Health emergency response: research, development and innovation	36
6. Monitoring, evaluating, testing and revising plans	37
6.1 Monitoring and evaluation	37
6.2 Testing and revising plans	38


Potenziamento della sorveglianza virologica



Current Flu season (2025-2026)



Current Flu season (2025-2026)



Phylogenetic comparison of Influenza A(H3N2)-lineage HA genes.
Sub-sampled GISAID EpiFlu submissions since 1 May 2025 as of 17 November 2025.


Reference strain (black)

Vaccine strain (red)


- * WHO recommended vaccine virus from the 2022 southern hemisphere to the 2023-2024 northern hemisphere influenza seasons
- ** WHO recommended vaccine virus from the 2024 southern hemisphere to the 2024-2025 northern hemisphere influenza seasons
- *** WHO recommended vaccine virus from the 2025 southern hemisphere to the 2025-2026 northern hemisphere influenza seasons
- **** WHO recommended vaccine virus for the 2026 southern hemisphere influenza season

Collection dates:

May
June
July
August
September
October



K (former J.2.4.1)



K2N,
T135K
S144N
N158D
I160K
Q173R
K189R
T328A
S378N

The newly emerged A(H3N2) subclade K (former J.2.4.1) belong to the dominating clade 2a.3a.1 and have K2N, T135K, S144N(+CHO), N158D, I160K, Q173R, K189R, T328A and S378N (haemagglutinin subunit 2: S49N) substitutions in haemagglutinin gene compared to A/Croatia/10136RV/2023, which is the WHO recommended eggpropagated vaccine virus for the 2025-2026 northern hemisphere influenza season.

Current Flu season (2025-2026) strain in Pavia

**WHO recommended vaccine virus from the 2022 southern hemisphere to the 2023–2024 northern hemisphere influenza season


*WHO recommended vaccine virus from the 2026 southern hemisphere influenza season

Month



- a April
- a August
- a December
- a February
- a January
- a July
- a June
- a March
- a May
- a November
- a October
- a Septmber

Lineage

- K
- Other
- Pavia



K lineage



Opinion

Next-Generation Sequencing: An Eye-Opener for the Surveillance of Antiviral Resistance in Influenza

Laura A.E. Van Poelvoorde,^{1,2,3,4,5,6} Xavier Saelens,^{3,4} Isabelle Thomas,^{2,6} and Nancy H. Roosens^{1,5,*}

Van Poelvoorde, Laura A E et al. "Trends in biotechnology vol. 38,4 (2020): 360-367. doi:10.1016/j.tibtech.2019.09.009

Although **vaccines** are considered the best way to prevent influenza, the limited use and their generally poor effectiveness in the elderly (<https://www.cdc.gov/flu/about/qa/vaccineeffect.htm>) imply that efficient antiviral drugs are needed as a complementary or alternative line of defense.

Monitoring and detecting mutations in the influenza virus genome by NGS, especially those that confer antiviral resistance, is of paramount importance to *public health surveillance*. As the use of antiviral drugs continues to grow, more cases of drug-resistant viruses are expected to occur.

- The HA proteins of the **human seasonal H1 and H3 virus** subtypes mainly recognize receptors with terminal **α -2,6-SA** moieties, which are found on bronchial epithelial cells of the human upper respiratory tract (URT).
- By contrast, **Avian viruses** bind predominantly to galactose linked to **α -2,3-SA₅₄**, which is found abundantly on epithelial cells in the intestine of birds and in the lower respiratory tract (LRT) of humans.

INFLUENZA



A single mutation in bovine influenza H5N1 hemagglutinin switches specificity to human receptors

Ting-Hui Lin¹, Xueyang Zhu¹, Shengyang Wang^{2,3}, Ding Zhang¹, Ryan McBride^{2,3}, Wenli Yu¹, Simeon Babarinde¹, James C. Paulson^{2,3*}, Ian A. Wilson^{1*}


In 2024, several human infections with highly pathogenic clade 2.3.4.4b bovine influenza H5N1 viruses in the United States raised concerns about their capability for bovine-to-human or even human-to-human transmission. In this study, analysis of the hemagglutinin (HA) from the first-reported human-infecting bovine H5N1 virus (A/Texas/37/2024, Texas) revealed avian-type receptor binding preference. Notably, a Gln²²⁶Leu substitution switched Texas HA binding specificity to human-type receptors, which was enhanced when combined with an Asn²²⁴Lys mutation. Crystal structures of the Texas HA with avian receptor analog LSTa and its Gln²²⁶Leu mutant with human receptor analog LSTc elucidated the structural basis for this preferential receptor recognition. These findings highlight the need for continuous surveillance of emerging mutations in avian and bovine clade 2.3.4.4b H5N1 viruses.

HA Gln226 → Leu
Shift from α -2,3-SA to α -2,6-SA

Thus, it is important to continue to monitor for signs of such changes in the currently circulating H5N1 viruses



<https://doi.org/10.1186/1746-6148-6-4>



<https://doi.org/10.1002/emboj.201387442>



Adaptation of Human Influenza Viruses to Swine

Daniela S. Rajao^{1*}, Amy L. Vincent² and Daniel R. Perez¹

¹ Department of Population Health, University of Georgia, Athens, GA, United States, ² Virus and Prion Research Unit, USDA-ARS, National Animal Disease Center, Ames, IA, United States






FIGURE 1 | Overall distribution of α 2,6-linked sialic acid (SA; green long arrow) and α 2,3-linked SA (blue short arrow) in the epithelium of the respiratory tract of pigs (18, 19) and humans (14, 15). Adapted from de Graaf and Fouchier (20).

A large diversity of influenza A viruses (IAV) within the H1N1/N2 and H3N2 subtypes circulates in pigs globally, with different lineages predominating in specific regions of the globe. A common characteristic of the ecology of IAV in swine in different regions is the **periodic spillover of human seasonal viruses**.

Such human viruses resulted in **sustained transmission in swine in several countries**, leading to the establishment of novel IAV lineages in the swine host and contributing to the genetic and antigenic diversity of influenza observed in pigs.

The frequent occurrence of reverse-zoonosis of IAV from humans to pigs that have contributed to the **global viral diversity in swine in a continuous manner**, describe host-range factors that may be related to the adaptation of these human-origin viruses to pigs, and how these events could affect the swine industry.



Swine H1 viruses



	190	225
Dual-binding or $\alpha 2,3$ -SA preference	E	G
	E	D
	D	G
$\alpha 2,6$ -SA preference	D	D
	D	E

15-20%



Swine H3 viruses



	226	228
Dual-binding or $\alpha 2,3$ -SA preference	Q	G
$\alpha 2,6$ -SA preference	L	S
	L	G
	V	S

<1%

Swine H9 viruses



	226	228
$\alpha 2,3$ -SA preference	Q	G
Dual-binding or $\alpha 2,6$ -SA preference	L	S

55%

FIGURE 3 | Proportion of amino acids found in influenza A viruses circulating in pigs globally at the HA receptor-binding site positions previously shown to impact receptor-specificity for H1, H3, and H9. Analysis was performed using the Influenza Research Database Sequence Variation (SNP) tool (44). Sequences with 100% identity were removed resulting in a set of 8076 H1 HA, 2287 H3 HA, and 46 H9 HA swine IAV sequences. The amino acids previously shown to change receptor-binding specificity are displayed on the right.

Swine influenza virus infection in humans: NGS approach

Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 21, No. 7, July 2015

DISPATCHES

Swine Influenza A(H3N2) Virus Infection in Immunocompromised Man, Italy, 2014

Antonio Piralla, Ana Moreno, Maria Ester Orlandi, Elena Percivalle, Chiara Chiapponi, Fausto Vezzoli, Fausto Baldanti, and the Influenza Surveillance Study Group¹

subtypes H1 and H3, as well as avian influenza subtype H7N9, were unsuccessful.

The clinical sample was inoculated onto a mixed-cell (Mv1Lu and A549 cells) monolayer. After 48 h incubation, it spread positive using a monoclonal antibody specific for

RAPID COMMUNICATIONS

Swine influenza A (H1N1) virus (SIV) infection requiring extracorporeal life support in an immunocompetent adult patient with indirect exposure to pigs, Italy, October 2016

F Rovida^{1,2}, A Piralla^{1,2}, FC Marzani³, A Moreno⁴, G Campanini¹, F Mojoli^{3,5}, M Pozzi³, A Girello¹, C Chiapponi⁶, F Vezzoli⁷, P Prati⁸, E Percivalle¹, A Pavan⁹, M Gramegna¹⁰, GA Iotti^{3,5}, F Baldanti^{1,11}






OPEN ACCESS

EDITED BY
Haibo Wu,
Zhejiang University, ChinaREVIEWED BY
Ruth H. Nisly,
The Pennsylvania State University (PSU),
United StatesZoonosis and
zooanthroponosis of
emerging respiratory virusesAhmed Magdy Khalil^{1,2}, Luis Martinez-Sobrido^{1*}
and Ahmed Mostafa^{1,3*}

IAVs are categorized according to their intermediate or ancestor animal host species into avian influenza viruses (AIVs), equine influenza viruses (EIVs), canine influenza viruses (CIVs), swine influenza viruses (SIVs) or bat-origin influenza-like viruses (BIVs).



[illegible]

Human case in Texas is the fourth reported case having

Americas, the most recorded

in

9 April 2024
Avian Influenza A(H5N1)
- United States of America

13 February 2024 | Avian Influenza A(H10N5) and Influenza A(H3N2) coinfection – China -

11 June 2024
Avian Influenza A (H9N2) - India

2 April 2024 | Avian Influenza A(H5N1) - Viet Nam

19 April 2024 | Avian Influenza A(H9N2) - Viet Nam

8 February 2024 | Avian Influenza A (H5N1) - Cambodia

7 June 2024 | Avian Influenza A (H5N1) - Australia

20 September 2024 | Avian Influenza A(H9N2) - Ghana

5 June 2024 | Avian Influenza A(H5N2) - Mexico

2021 2024



Pandemic risk characterisation of zoonotic influenza A viruses using the Tool for Influenza Pandemic Risk Assessment (TIPRA)

Reina Yamaji, Wenqing Zhang, Akiko Kamata, Cornelia Adlhoch, David E Swayne, Dmitriy Pereyaslov, Dayan Wang, Gabriele Neumann, Gounalan Pavade, Ian G Barr, Malik Peiris, Richard J Webby, Ron A M Fouchier, Sophie Von Dobschütz, Thomas Fabrizio, Yuelong Shu, Magdi Samaan



1. Scores viruses across two dimensions

TIPRA evaluates a zoonotic influenza virus using two main axes:

- (a) Risk of Emergence (how likely the virus is to gain sustained human-to-human transmission) and
- (b) Potential Public-Health Impact (how severe a pandemic would be if it emerged).

2. Uses a set of predefined indicators


Each axis is broken down into quantitative and qualitative indicators (e.g., transmissibility in mammals, genetic markers, human case severity, population immunity, global spread in animals). Experts assign standardized scores to each indicator.

3. Relies on multidisciplinary expert judgment

TIPRA integrates evidence from virology, epidemiology, surveillance data, ecology, clinical severity, and immunology. Experts review available data, discuss uncertainties, and assign final consensus scores for each indicator.



4. Produces a comparable “risk profile” across viruses

The tool summarizes the scoring into an emergence-risk score, an impact score, and an overall risk characterization, allowing WHO and member states to compare different zoonotic influenza viruses, prioritize surveillance, and guide preparedness actions.



Pandemic risk characterisation of zoonotic influenza A viruses using the Tool for Influenza Pandemic Risk Assessment (TIPRA)

Reina Yamaji, Wenqing Zhang, Akiko Kamata, Cornelia Adlhoch, David E Swayne, Dmitriy Pereyaslov, Dayan Wang, Gabriele Neumann, Gounalan Pavade, Ian G Barr, Malik Peiris, Richard J Webby, Ron A M Fouchier, Sophie Von Dobschütz, Thomas Fabrizio, Yuelong Shu, Magdi Samaan



Emergenet: Fast Scalable Pandemic Risk Assessment of Influenza A Strains Circulating In Non-human Hosts


Kevin Wu¹, Jin Li¹, Aaron Esser-Kahn^{2,3}, and Ishanu Chattopadhyay^{1,4,5}★

¹ Department of Medicine, University of Chicago, IL, USA


² Pritzker School of Molecular Engineering, University of Chicago, Chicago, IL, USA

³ Committee on Immunology, University of Chicago, Chicago, IL, USA


⁵ Committee on Quantitative Methods in Social, Behavioral, and Health Sciences, University of Chicago, IL, USA




A. Predicted emergence risk vs published IRAT scores




b. Estimating emergence



c. Estimating impact



d. Global prediction of IRAT scored for all Influenza A sequences collected since 2020





**Grazie
per
l'attenzione**

